SLC5A2 and lung adenocarcinoma: found that SGLT2 was mainly expressed in precancerous lesions and early, well-differentiated lung adenocarcinoma;in mouse experiments, it was shown that the tumor proliferation rate of the canagliflozin treatment group was significantly reduced, but only for precancerous lesions, not for solid lung adenocarcinoma, indicating that SGLT2i may target precancerous lesions and its efficacy is higher than that of advanced tumors, suggesting that SGLT2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma (26).